Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Characteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process

Full metadata record
DC Field Value Language
dc.contributor.authorChun, Nan-Hee-
dc.contributor.authorWang, In-Chun-
dc.contributor.authorLee, Min-Jeong-
dc.contributor.authorJung, Yun-Taek-
dc.contributor.authorLee, Sangkil-
dc.contributor.authorKim, Woo-Sik-
dc.contributor.authorChoi, Guang J.-
dc.date.accessioned2021-08-12T00:44:37Z-
dc.date.available2021-08-12T00:44:37Z-
dc.date.issued2013-11-
dc.identifier.issn0939-6411-
dc.identifier.issn1873-3441-
dc.identifier.urihttps://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13246-
dc.description.abstractThe creation of co-crystals of various insoluble drug substances has been extensively investigated as a promising approach to improve their pharmaceutical performance. In this study, co-crystal powders of indomethacin and saccharin (IMC-SAC) were prepared by an anti-solvent (water) addition and compared with co-crystals by evaporation method. No successful synthesis of a pharmaceutical co-crystal powder via an anti-solvent approach has been reported. Among solvents examined, methanol was practically the only one that resulted in the formation of highly pure IMC-SAC co-crystal powders by anti-solvent approach. The mechanism of a preferential formation of IMC-SAC co-crystal to IMC was explained with two aspects: phase solubility diagram and solution complexation concept. Accordingly, the anti-solvent approach can be considered as a competitive route for producing pharmaceutical co-crystal powders with acceptable properties. (C) 2013 Elsevier By. All rights reserved.-
dc.format.extent8-
dc.language영어-
dc.language.isoENG-
dc.publisherElsevier BV-
dc.titleCharacteristics of indomethacin-saccharin (IMC-SAC) co-crystals prepared by an anti-solvent crystallization process-
dc.typeArticle-
dc.publisher.location네델란드-
dc.identifier.doi10.1016/j.ejpb.2013.02.007-
dc.identifier.wosid000330200800005-
dc.identifier.bibliographicCitationEuropean Journal of Pharmaceutics and Biopharmaceutics, v.85, no.3, pp 854 - 861-
dc.citation.titleEuropean Journal of Pharmaceutics and Biopharmaceutics-
dc.citation.volume85-
dc.citation.number3-
dc.citation.startPage854-
dc.citation.endPage861-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClasssci-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.subject.keywordPlusPHARMACEUTICAL COCRYSTALS-
dc.subject.keywordPlusBIOAVAILABILITY-
dc.subject.keywordPlusDRUGS-
dc.subject.keywordAuthorCo-crystal-
dc.subject.keywordAuthorIndomethacin-
dc.subject.keywordAuthorSaccharin-
dc.subject.keywordAuthorAnti-solvent crystallization-
dc.subject.keywordAuthorMechanism-
dc.subject.keywordAuthorDissolution rate-
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medical Sciences > Department of Pharmaceutical Engineering > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE